Fate Therapeutics Bolsters Academic Stem-Cell IP Portfolio with Whitehead Institute License

The deal brings to six the number of academic institutions from which Fate has licensed IP related to using small molecules to induce pluripotency in stem cells for therapeutic effect, drug discovery, and matched cell-replacement therapies.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.